...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS >Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors.
【24h】

Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors.

机译：围产期暴露于核苷逆转录酶抑制剂的儿童患癌症的可能性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

CONTEXT: Long-term studies of tolerance to perinatal exposure to antiretroviral nucleoside reverse transcriptase inhibitors are required, in view of the potential genotoxicity of some of these molecules. OBJECTIVE: To evaluate the incidence of cancers in uninfected children born to HIV-infected mothers. METHOD: Cancers were detected in a nationwide prospective cohort of children born to HIV-infected mothers by standardized questionnaire during the prospective follow-up period of 2 years; thereafter, they were detected by spontaneous pharmacovigilance declaration and by crosschecking data with the national registries of childhood cancer. Standardized incidence ratio for incidence comparisons with general population. RESULTS: Ten cases of cancer were detected among the 9127 exposed HIV-uninfected children (median age: 5.4 years, 53 052 person-years of follow-up). The overall incidence did not differ significantly from that expected for the general population: 10 cases observed versus 8.9 and 9.6 expecteddepending on whether 1990-1999 or 2000-2004 national rates were used as reference [standardized incidence ratio of 1.1 (0.3-1.5) and 1.0 (0.5-1.9)]. Five cases of central nervous system cancer were observed (standardized incidence ratio of 3.1 [1.0-7.2] P = 0.05 and 2.4 [0.8-5.6], P = 0.12). The relative risk of cancer for children exposed to didanosine-lamivudine combination was higher than that for zidovudine monotherapy [hazard ratio: 13.6 (2.5-73.9)]. CONCLUSION: This study did not evidence an overall increase in cancer risk in nucleoside reverse transcriptase inhibitor exposed children until 5 years of age. Results suggesting associations with specific nucleoside reverse transcriptase inhibitor combinations need further investigations. A longer surveillance, including differential analysis of the different cancer sites and various nucleoside reverse transcriptase inhibitors administered is warranted.
机译：背景：鉴于某些分子的潜在遗传毒性，需要对围产期接受抗逆转录病毒核苷逆转录酶抑制剂的耐受性进行长期研究。目的：评估艾滋病毒感染母亲所生的未感染儿童的癌症发病率。方法：在为期2年的前瞻性随访期内，通过标准化调查表在全国范围内由HIV感染母亲所生的儿童中检测出癌症。此后，通过自发的药物警戒声明以及与国家儿童癌症登记处的数据交叉核对发现了它们。用于与一般人群进行发病率比较的标准化发病率。结果：在9127例暴露的未感染HIV的儿童中检测到10例癌症（中位年龄：5.4岁，随访时间为53052人年）。总发病率与一般人群的预期发病率没有显着差异：观察到的10例病例与预期的8.9和9.6例发病率有关，具体取决于将1990-1999年或2000-2004年全国比率作为参考[标准发病率1.1（0.3-1.5）和1.0（0.5-1.9）]。观察到五例中枢神经系统癌症病例（标准化发病率分别为3.1 [1.0-7.2] P = 0.05和2.4 [0.8-5.6]，P = 0.12）。接受二羟肌苷-拉米夫定联合治疗的儿童的相对癌症风险高于齐多夫定单药治疗[风险比：13.6（2.5-73.9）]。结论：这项研究没有证据表明暴露于核苷类逆转录酶抑制剂的儿童直到5岁之前，其癌症风险总体增加。结果提示与特定核苷逆转录酶抑制剂组合的关联需要进一步研究。有必要进行更长的监测，包括对不同癌症部位和所施用的各种核苷逆转录酶抑制剂的差异分析。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号